Akarna Therapeutics Ltd.

7 articles about Akarna Therapeutics Ltd.

• 

  Pfizer and Novartis Ink Deal to Test Combination Therapies for NASH

  10/29/2018

  NASH is similar to cirrhosis of the liver but occurs in people that drink little or no alcohol. It is related to the obesity epidemic and affects at least three to five percent of the adult population worldwide. Many believe that combination therapies will be the best way to approach treating NAS...
• 

  Startup Terns Secures Three NASH Assets From Eli Lilly

  4/4/2018

  The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.

• Forbion’s Portfolio Company Akarna Therapeutics Acquired By Allergan

  9/21/2016

• Allergan's NASH Spree Continues With $50 Million+ Buyout of San Diego's Akarna Therapeutics

  9/21/2016

• Akarna Therapeutics Acquired By Allergan

  9/21/2016

• Akarna Therapeutics Announces Formation Of Clinical Advisory Board

  4/11/2016

• SoCal and UK-Based Startup Akarna Therapeutics Gets $15 Million

  2/16/2016